Vitura Health (ASX:VIT) Net-Net Working Capital: A$-0.02 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Vitura Health Net-Net Working Capital?

Vitura Health ASX:VIT -3.23% Net-Net Working Capital is A$-0.02 as of Dec. 2025. The stock has 8 warning signs investors should review. Among 415 Drug Manufacturers companies, Vitura Health ranks worse than 240963.61% on this metric.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Vitura Health's Net-Net Working Capital for the quarter that ended in Dec. 2025 was A$-0.02.

The industry rank for Vitura Health's Net-Net Working Capital or its related term are showing as below:

ASX:VIT's Price-to-Net-Net-Working-Capital is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.8
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

Vitura Health  (ASX:VIT) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Vitura Health Net-Net Working Capital Related Terms


Vitura Health Net-Net Working Capital Historical Data

* Premium members only.

The historical data trend for Vitura Health's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vitura Health Net-Net Working Capital Chart

Vitura Health Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Net-Net Working Capital
Get a 7-Day Free Trial 0.05 0.01 0.03 -0.02 -0.01

Vitura Health Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.02 -0.02 -0.01 -0.02

ASX:VIT vs ZTS, UTHR: Net-Net Working Capital Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vitura Health's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vitura Health Price-to-Net-Net-Working-Capital vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vitura Health's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Vitura Health's Price-to-Net-Net-Working-Capital falls into.



Vitura Health Net-Net Working Capital Calculation

Vitura Health's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Jun. 2025 is calculated as

Net-Net Working Capital(A: Jun. 2025 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(7.579+0.75 * 10.004+0.5 * 5.978-27.893
-0--0.602)/662.255
=-0.01

Vitura Health's Net-Net Working Capital (NNWC) per share for the quarter that ended in Dec. 2025 is calculated as

Net-Net Working Capital(Q: Dec. 2025 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(6.1+0.75 * 12.879+0.5 * 6.889-31.491
-0--0.751)/662.742
=-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.

What does a Net-Net Working Capital of A$-0.02 mean?
Vitura Health (ASX:VIT) has a Net-Net Working Capital of A$-0.02 as of Dec. 2025. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Vitura Health According to the industry distribution chart, Vitura Health ranks #999999 out of 415 companies in the Drug Manufacturers industry.
Is Vitura Health's Net-Net Working Capital too high?
Vitura Health's current Net-Net Working Capital is A$-0.02. Based on the distribution chart, Vitura Health ranks #999999 out of 415 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Vitura Health's Net-Net Working Capital compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vitura Health ranks #999999 out of 415 companies for Net-Net Working Capital. This places Vitura Health in the lower half of its industry. The industry median Net-Net Working Capital is 7.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Drug Manufacturers company?
The median Net-Net Working Capital among Drug Manufacturers companies is 7.80, based on 415 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Vitura Health For the Drug Manufacturers industry, the median Net-Net Working Capital is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitura Health's current Net-Net Working Capital is A$-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitura Health stock overvalued right now?
Based on GuruFocus' analysis, Vitura Health (ASX:VIT) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.10, compared to a current price of A$0.03 — trading 70% below its estimated fair value. The current Net-Net Working Capital is A$-0.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Vitura Health (ASX:VIT), the current Net-Net Working Capital is A$-0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vitura Health Business Description

Address 299 Toorak Road, Suite 8, Level 3, South Yarra, VIC, AUS, 3141
Vitura Health Ltd is focused on creating medicinal cannabis products and digital health solutions that connect and strengthen the ecosystem between patients, prescribers, pharmacists, and suppliers. The company has two business segments namely, Sales and distribution (involving the sale and distribution of medical products including medicinal cannabis, psychedelic drugs, and smoking cessation products) and Clinics and services (involving the operation of medicinal cannabis clinics and the provision of related services). The company generates the majority of its revenue from the Sales and distribution segment. Geographically the company generates the majority of its revenue from Australia.